PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | C0022661|end stage renal disease |
| Sentences | 4 |
| PubMedID- 22020086 | Increased vascular calcification, possibly due to the biochemical problem of calcium (ca) and phosphate excess, has been associated with cardiovascular disease in patients with end stage renal disease. |
| PubMedID- 26000261 | Background: hyperhomocysteinemia is a risk factor for cardiovascular disease particularly in patients with end stage renal disease (esrd). |
| PubMedID- 23335472 | In 2006, flores-mateo et al reported that the use of supplements containing selenium did not reduce the risk of coronary heart disease in the meta-analysis of six trials.6 more recently, however, lee et al found that folic acid supplementation with b vitamins had potential small benefits in the prevention of stroke,7 and qin et al indicated that folic acid treatment decreased the risk of cardiovascular disease by 15% in patients with end stage renal disease or advanced chronic kidney disease.8 even though several meta-analyses of randomised controlled trials have been published regarding the efficacy of vitamins and antioxidant supplements on cardiovascular diseases, they involved individual vitamins or antioxidants, and there was no published comprehensive meta-analysis that reviewed this topic all together in one report. |
| PubMedID- 22489274 | Similarly, the secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (space) trial [137], study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin e (secure) trial [138], and the primary prevention project (ppp) trial [139] all failed to show beneficial effects of antioxidants in diabetes-associated cardiovascular disease. |
Page: 1